Tags : Cirrhosis

AbbVie’s Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients

Shots: The marketing authorization is based on P-IIIb EXPEDITION-8 study assessing Maviret in 280 treatment-naive chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks. The P-IIIb EXPEDITION-8 study resulted in @8wks. 97.9% GT1, 2, 4, 5 & 6 patients achieved a sustained virologic response 12wks. (SVR12); no case of virologic failures […]Read More